CN101062029A - Application of wogonin in the preparing of medicine for treating gastric cancer - Google Patents
Application of wogonin in the preparing of medicine for treating gastric cancer Download PDFInfo
- Publication number
- CN101062029A CN101062029A CN 200710022464 CN200710022464A CN101062029A CN 101062029 A CN101062029 A CN 101062029A CN 200710022464 CN200710022464 CN 200710022464 CN 200710022464 A CN200710022464 A CN 200710022464A CN 101062029 A CN101062029 A CN 101062029A
- Authority
- CN
- China
- Prior art keywords
- wogonin
- gastric cancer
- medicine
- application
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of wogonin to prepare stomach cancer medicine in pharmacy domain, which is characterized by the following: possessing distinctive growth inhibitory action of the wogonin for human stomach cancer MGC803 bare mouse transplanting tumor. This invention provides better choice for stomach cancer patient.
Description
Technical field
The invention belongs to pharmaceutical field, relate to the new purposes of wogonin, be specifically related to the application of wogonin in the medicine of preparation treatment gastric cancer.
Background technology
Wogonin is Labiatae (Labiatase) plant Radix Scutellariae (Scutellaria baicalensis Georgi) and belongs to flavone compound contained in the root of various plants together, has the structure of formula (1).
Formula (1)
Studies show that wogonin has multiple pharmacological effect, comprise antioxidation, blood coagulation resisting function, spasmolysis, antibiotic in addition in addition, antivirus action and diuresis etc.Current research shows that wogonin can also suppress tumor cell proliferation.Report shows that wogonin can suppress ovarian cancer A2780 cell proliferation and cell death inducing, its Anticancer Effect and Mechanism is with apoptosis-induced relevant, the inhibition telomerase activation may play partial action, and (Li Danrong etc., wogonin induce the influence of Proliferation of Human Ovarian Cell A2780 apoptosis and pair cell telomerase activation." cancer " 2003 8 phases); Chinese patent literature CN1785175 also discloses the application of wogonin in the leukemic medicine of preparation treatment, is application in the medicine of directed differentiation at preparation inducing leukemia cell to grain particularly.But there is not the bibliographical information wogonin at present in the particularly application in the medicine of gastric cancer of preparation treatment digestive system tumor.
Summary of the invention
The purpose of this invention is to provide the application of wogonin in the medicine of preparation treatment gastric cancer.
The inventor finds that in research process wogonin not only can suppress leukemia, and the gastric cancer in the solid tumor is also had better curative effect, therefore proposes the application of wogonin in the medicine of preparation treatment gastric cancer.Wogonin can be made pharmaceutical composition with any one adjuvant that pharmaceutically allows among the present invention.Its preparation can be any one dosage form that pharmaceutically allows, and includes but not limited to tablet, granule, pill, oral liquid, injection, membrane, capsule, liposome etc.The consumption of wogonin can be according to variations such as route of administration, patient age, body weight, body surface area, the disease type of being treated and the orders of severity, and its daily dose can be 80-3600mg, can use by one or many.
Beneficial effect of the present invention:
The invention discloses the application of wogonin in the medicine of preparation treatment gastric cancer.Experimentation shows that wogonin has significant growth inhibited effect to people's Gastric Cancer MGC 803 Nude Mice.Chinese Radix Scutellariae is with 50mg/kg, and 25mg/kg intravenous administration, successive administration be in the time of 13 days, and the T/C (%) of people's Gastric Cancer MGC 803 Nude Mice is respectively 38.6%, 52.9%, and tumour inhibiting rate reaches 61.3%, 48.8% respectively.T/C (%) to people's Gastric Cancer MGC 803 Nude Mice when paclitaxel is with the 10mg/kg intravenous injection under the similarity condition is 43.6%, and tumour inhibiting rate is 56.4%.According to the present invention, wogonin can be prepared into the medicine of treatment gastric cancer, for patients with gastric cancer provides more alternative medicines.The toxic action of wogonin pair cell is less simultaneously, helps clinical practice.
The specific embodiment
The invention will be further elaborated by the following examples.
Drug effect embodiment 1
Experiment purpose: according to the requirement of new drug preclinical study guideline, the test wogonin has or not growth inhibited effect and action intensity to people's Gastric Cancer MGC 803 Nude Mice.
Be subjected to the reagent thing: wogonin, China Medicine University provides, wogonin normal saline solution suspendible before each administration.
Control drug: paclitaxel, Haikou Pharmaceutical Factory Co., Ltd. produces, lot number: 060804.Prepare desired concn with normal saline before each administration.
Dosage is provided with: the high dose of wogonin is 50mg/kg, and the low dosage of wogonin is 25mg/kg, and the dosage of paclitaxel is 10mg/kg.
Animal: the BALB/c nude mouse provides (laboratory animal production licence: SCXK (Shanghai) 2003-0003 by Shanghai Slac Experimental Animal Co., Ltd.; Laboratory animal occupancy permit: SYXK (Soviet Union) 2002-0053).Age in days: 35-40 days, body weight 18-22g, female, 6 every group.
Transplanted tumor: people's Gastric Cancer MGC 803 Nude Mice, it is subcutaneous and set up to be inoculated in the nude mouse axillary fossa by people's Gastric Cancer MGC 803 cell strains.The cell inoculation amount is 1 * 10
6, inoculation is used after forming and passing for 3 generations again in the nude mouse body after the transplanted tumor.
Experimental technique:
The tumor tissue of getting the growth animated period cuts into 1.5mm
3About, under aseptic condition, be prepared into 1 * 10 after the homogenate
7/ ml cell suspension, it is subcutaneous to be inoculated in nude mouse right side axillary fossa with 0.1ml.Nude Mice treats that with vernier caliper measurement transplanted tumor diameter tumor growth is to 100mm
3After with the animal random packet, 6 every group.Use the method for measuring the tumor footpath, dynamic observe tested thing antineoplastic effect.Wogonin is with 50mg/kg, 25mg/kg, intravenous administration, successive administration 13 days; Paclitaxel is with the 10mg/kg intravenous administration, successive administration 13 days.The measurement number of times of diameter of tumor is for every other day surveying once.The administration volume is 0.1ml/20g.Negative control group intravenous injection equivalent normal saline solution.After the administration 13 days, mice is put to death, and operation strips the tumor piece and weighs.Gross tumor volume (tumor volume, computing formula TV) is:
TV＝1/2×a×b
2
Wherein a, b represent length and width respectively.
(relative tumor volume, RTV), computing formula is: RTV=V to calculate relative tumour volume according to the result who measures
t/ V
0V wherein
0(d during for minute cage administration
0) measurement gained gross tumor volume, V
tGross tumor volume when measuring each time.The evaluation index of anti-tumor activity is relative tumor proliferation rate T/C (%), and computing formula is as follows:
T
RTV: treatment group RTV; C
RTV: negative control group RTV.
The result: wogonin sees Table 1 to the experimental therapeutic outcome of people's Gastric Cancer MGC 803 Nude Mice.Experimental result shows that wogonin has significant growth inhibited effect to people's Gastric Cancer MGC 803 Nude Mice.Wogonin is with 50mg/kg, and 25mg/kg intravenous administration, successive administration be in the time of 13 days, and the T/C (%) of people's Gastric Cancer MGC 803 Nude Mice is respectively 38.6%, 52.9%, and tumour inhibiting rate reaches 61.3%, 48.8% respectively.T/C (%) to people's Gastric Cancer MGC 803 Nude Mice when paclitaxel is with the 10mg/kg intravenous injection under the similarity condition is 4.01%, and tumour inhibiting rate is 94.9%.
Conclusion: wogonin has significant inhibitory effect to the growth of people's Gastric Cancer MGC 803 Nude Mice.
The inhibitory action that table 1 wogonin is grown to MGC803 people's gastric cancer bare mouse different species transplantation tumor (X ± SD)
| Group | Dosage (mg/kg) | Initial body weight (g) | Initial number of animals | Whole opisthosoma heavy (g) | Whole last number of animals | Tumor heavy (g) | Tumour inhibiting rate (%) |
| The blank group | - | 18.2±1.4 | 6 | 21.0±0.9 | 6 | 0.727±0.323 | - |
| The paclitaxel matched group | 10 | 18.1±0.5 | 6 | 20.5±0.9 | 6 | 0.317±0.051 ** | 56.4 |
| The wogonin high dose group | 50 | 18.2±0.9 | 6 | 19.6±1.0 | 6 | 0.281±0.167 ** | 61.3 |
| The wogonin low dose group | 25 | 18.1±0.7 | 6 | 20.0±1.6 | 6 | 0.372±0.191 ** | 48.8 |
Compare with the blank group,
*P＜0.01
Example of formulations 1
Get wogonin 10g, add suitably adjuvant of injection (comprising lyophilized injectable powder and aseptic subpackaged dry powder injection), become anti-gastric cancer medicine injection by injection (comprising lyophilized injectable powder and aseptic subpackaged dry powder injection) prepared.
Example of formulations 2
Get wogonin 10g, add suitably adjuvant of tablet (comprising slow-release tablet, matrix tablet, coated tablet, dispersible tablet etc.), become anti-gastric cancer tablet by tablet (comprising slow-release tablet, matrix tablet, coated tablet, dispersible tablet etc.) prepared.
Example of formulations 3
Get wogonin 10g, add the suitable adjuvant of capsule, become the agent of anti-gastric cancer Drug Capsule by the capsule prepared.
Example of formulations 4
Get wogonin 10g, add the suitable adjuvant of oral liquid, become anti-gastric cancer medicine oral liquid by the oral liquid prepared.
Claims (1)
1, the application of wogonin in the medicine of preparation treatment gastric cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710022464A CN101062029B (en) | 2007-05-21 | 2007-05-21 | Application of wogonin in the preparing of medicine for treating gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710022464A CN101062029B (en) | 2007-05-21 | 2007-05-21 | Application of wogonin in the preparing of medicine for treating gastric cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101062029A true CN101062029A (en) | 2007-10-31 |
| CN101062029B CN101062029B (en) | 2010-05-19 |
Family
ID=38963449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710022464A Active CN101062029B (en) | 2007-05-21 | 2007-05-21 | Application of wogonin in the preparing of medicine for treating gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101062029B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102525929A (en) * | 2012-02-23 | 2012-07-04 | 中国药科大学 | Wogonin liposome preparation modified with glycyrrhetinic acid and preparation method thereof |
| CN103230398A (en) * | 2013-04-10 | 2013-08-07 | 中国药科大学 | Applications of a Wogonin derivative in the preparation of antineoplastic drugs |
| CN105287488A (en) * | 2015-10-12 | 2016-02-03 | 安徽医科大学 | Application of wogonin in treating acute kidney injury and medicine prepared by wogonin for treating acute kidney injury |
| CN105497007A (en) * | 2015-12-18 | 2016-04-20 | 杭州市第一人民医院 | Medicine composition for treating gastrointestinal cancer |
| CN117045639A (en) * | 2023-09-27 | 2023-11-14 | 山东益康药业股份有限公司 | Pharmaceutical composition for treating gastric cancer and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037193A2 (en) * | 2002-10-22 | 2004-05-06 | Jenken Biosciences, Inc. | Chromones and chromone derivatives and uses thereof |
-
2007
- 2007-05-21 CN CN200710022464A patent/CN101062029B/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102525929A (en) * | 2012-02-23 | 2012-07-04 | 中国药科大学 | Wogonin liposome preparation modified with glycyrrhetinic acid and preparation method thereof |
| CN103230398A (en) * | 2013-04-10 | 2013-08-07 | 中国药科大学 | Applications of a Wogonin derivative in the preparation of antineoplastic drugs |
| CN103230398B (en) * | 2013-04-10 | 2015-05-13 | 中国药科大学 | Applications of a Wogonin derivative in the preparation of antineoplastic drugs |
| CN105287488A (en) * | 2015-10-12 | 2016-02-03 | 安徽医科大学 | Application of wogonin in treating acute kidney injury and medicine prepared by wogonin for treating acute kidney injury |
| CN105497007A (en) * | 2015-12-18 | 2016-04-20 | 杭州市第一人民医院 | Medicine composition for treating gastrointestinal cancer |
| CN117045639A (en) * | 2023-09-27 | 2023-11-14 | 山东益康药业股份有限公司 | Pharmaceutical composition for treating gastric cancer and application thereof |
| CN117045639B (en) * | 2023-09-27 | 2024-04-02 | 山东益康药业股份有限公司 | Pharmaceutical composition for treating gastric cancer and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101062029B (en) | 2010-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105769891B (en) | Low polarity rare ginsenoside mixture and application thereof | |
| CN101062029B (en) | Application of wogonin in the preparing of medicine for treating gastric cancer | |
| CN1374288A (en) | Gronwell naphthaquinone derivative and its application in preparing anticancer medicine | |
| CN100336552C (en) | Medicine for treating lung cancer | |
| Ali | In vitro studies of antimicrobial activity of (Curcuma longa L.) rhizomes against helicobacter pylori | |
| CN109568587A (en) | Pharmaceutical combination preparations and radix aucklandiae, Radix Aucklandiae extract are preparing the application in chemotherapeutics Synergy and attenuation agent | |
| CN102600120B (en) | Application of cinnamic acid in preparation of drugs for preventing and treating livestock and poultry virus infection | |
| CN104055786A (en) | Medicagenic acid-3-O-beta-D-glucopyranoside and medicagenic acid and application of salt of medicagenic acid-3-O-beta-D-glucopyranoside and medicagenic acid to preparation of medicine for preventing and treating tumor | |
| CN110559287A (en) | Pharmaceutical composition for treating cancer and application thereof | |
| CN104971077B (en) | A kind of new application of Cynanchum Wallichii total saposins | |
| CN108186740A (en) | Meadowrueleaf corydalis root prepares treatment intestinal disorder drug or health products and application with its extract | |
| CN106928298A (en) | The structure composition of ring dinucleotides cGAMP derivatives, preparation method and its application in antitumor | |
| CN103877126B (en) | Knurl lid intends the pharmaceutical usage of shelf fungus and the pharmaceutical composition for the treatment of tumour | |
| CN117045639B (en) | Pharmaceutical composition for treating gastric cancer and application thereof | |
| RU2077888C1 (en) | Method of treatment of radiation disease in animals | |
| CN109692225A (en) | A kind of new application of Dabaidu Capsules | |
| CN102440994A (en) | Application of ganoderic acid G as immune synergist and super-antigen dependent therapeutic medicine in tumour treatments | |
| CN104173354B (en) | Can treating cancer pharmaceutical compositions | |
| CN109350620B (en) | A kind of drug and application thereof for treating oophoroma | |
| CN111467367B (en) | Plant monomer composition for inhibiting tumor cell growth and preparation method and application thereof | |
| CN101138587A (en) | Application of white fleece-flower root or white fleece-flower root diketone A in the preparation of medicament for treating neurological disorders | |
| CN1781548A (en) | Medicinal preparation for treating stomach and intestine diseases and its preparing method | |
| Mahalakshmi et al. | ANTIOXIDANT AND ANTI-INFLAMMATORY PROPERTIES OF RHODIOLA ROSEA NANOPARTICLES IN AN INVITRO MODEL | |
| CN1883521A (en) | Application of Rangoon creeper fruit and its extracts in preparation of medicine for promoting lead expelling | |
| CN1273173C (en) | New use of medicine for preventing and treating radiative damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HEFEI COSOURCE MEDICINE TECHNOLOGY CO., LTD. Effective date: 20131231 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20131231 Address after: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee after: China Pharmaceutical University Patentee after: Hefei Cosource Medicine Technology Co., Ltd. Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee before: China Pharmaceutical University |